Richard Alan Lafayette MD
Professor, Medicine - Nephrology, Stanford University Medical Center
Join to View Full Profile
300 Pasteur DrPalo Alto, CA 94305
Phone+1 650-725-6186
Fax+1 650-725-8418
Dr. Lafayette is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Stanford Health Care-Sponsored Stanford UniversityFellowship, Nephrology, 1988 - 1991
Zucker School of Medicine at Hofstra/NorthwellResidency, Internal Medicine, 1985 - 1987
New York Medical CollegeClass of 1985
Certifications & Licensure
CA State Medical License 1988 - 2027
MA State Medical License 1992 - 1996
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Nephrology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2012-2014, 2016-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2012-2014, 2016-2017
- Regional Top Doctor Castle Connolly, 2014
Clinical Trials
- Immunosuppression Impact on the Metabolic Control of Kidney Transplant With Pre-Existing Type 2 Diabetes (DM) Start of enrollment: 2005 Jun 01
- Rituximab in Progressive Immunoglobulin A (IgA) Nephropathy Start of enrollment: 2009 Feb 01
- MEmbranous Nephropathy Trial Of Rituximab Start of enrollment: 2011 Nov 01
Publications & Presentations
PubMed
- Current trial landscape of IgA nephropathy therapy.Jackson Kim, Fahmeedah Kamal, Richard Lafayette
Med. 2026-01-09 - Modern challenges in infection prevention: encapsulated organisms in the era of novel complement inhibitors.Ayman Al Jurdi, Camille N Kotton, Richard Lafayette
Kidney International. 2025-12-25 - Defining Disease Modification in IgA Nephropathy: Toward a Paradigm Shift in Management.Jonathan Barratt, Laura H Mariani, Jai Radhakrishnan, Dana V Rizk, James A Tumlin
Kidney International Reports. 2025-12-01
Journal Articles
- Cause of Kidney Disease and Cardiovascular Events in a National Cohort of US Patients with End-Stage Renal Disease on Dialysis: A Retrospective AnalysisWolfgang C Winkelmayer, Richard A Lafayette, European Heart Journal
Abstracts/Posters
- Facing the Vexing Problem of Recurrent FSGS After Kidney TransplantationRichard Lafayette, MD, American Society of Nephrology, Orlando, FL, 12/7/2019
- Facing the Vexing Problem of Recurrent FSGS After Kidney TransplantationRichard Lafayette, MD, American Society of Nephrology, Orlando, FL, 12/7/2019
Press Mentions
ORIGIN Phase 3 Trial Confirms Atacicept’s Efficacy in IgANNovember 10th, 2025- Vertex Presents Updated Phase 1/2 Data from RUBY-3 Study That Continue to Demonstrate Best-in-Class Potential for Povetacicept in Adults with IgA Nephropathy and Primary Membranous Nephropathy at American Society of Nephrology Kidney WeekNovember 8th, 2025
- ‘Save a Lifetime’: Pediatric Doctors Receive $15 Mil. DonationOctober 15th, 2025
Grant Support
- Oral Calcimimetic Agent In Secondary HyperparathyroidismNational Center For Research Resources2000–2001
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
